Location · Waterford, CT
Clinical trials in Waterford, CT
9 recruiting studies have a site in Waterford, and 0 of them accept healthy volunteers.
9 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Merck Sharp & Dohme LLC
- Location
- Waterford, CT + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Boehringer Ingelheim
- Location
- Waterford, CT + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Amgen
- Location
- Waterford, CT + 54 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies, Inc.
- Location
- Waterford, CT + 78 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
ONL Therapeutics
- Location
- Waterford, CT + 55 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2/Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
EyeBiotech Ltd.
- Location
- Waterford, CT + 51 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or…
Ocular Therapeutix, Inc.
- Location
- Waterford, CT + 7 other US sites
- Eligibility basics
- Ages 50+
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
Kodiak Sciences Inc
- Location
- Waterford, CT + 47 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
Kodiak Sciences Inc
- Location
- Waterford, CT + 47 other US sites
- Eligibility basics
- Ages 18+